Scorpius Holdings Announces Contract with Premier Clinical-Stage Biotech Company; Opens Door to Future GMP Manufacturing Opportunities
Tuesday, October 01, 2024
Scorpius Holdings, Inc., an integrated contract development and manufacturing organization ("CDMO"), announced it has signed a contract to provide bioanalytical services for a publicly traded clinical-stage immuno-oncology company.
This collaboration opens the door for further opportunities, as Scorpius expects to expand its services to include additional analytical work and future GMP manufacturing upon completion of this initial phase. This contract underscores Scorpius’ expertise in delivering critical bioanalytical and process development services, further establishing its role as a trusted partner in the biologics manufacturing space.
Jeff Wolf, CEO of Scorpius, commented, "This important contract is a clear validation of Scorpius’ comprehensive capabilities which include advanced bioanalytical services. Our state-of-the-art bioanalytical and process development facilities enable us to offer an integrated solution that meets the diverse needs of biologics manufacturers. We are excited by the potential to develop this partnership further and to offer ongoing bioanalytical support and future GMP manufacturing services to help advance this client’s clinical programs.”
Source: globenewswire.com
